Log in or register to see all Alerts
New HTA Decisions in England
August 2020
Drug name
TECENTRIQ® (atezolizumab)
Company
Roche
Decision date
//
Therapeutic area
Cancer
Therapeutic sub area
Lung cancer
Decision
Not recommended
Indication
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer because the company did not make an evidence submission.